EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioGaia AB's enterprise value is kr10,362 Mil.
BioGaia AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr495 Mil. Therefore, BioGaia AB's EV-to-EBITDA for today is 20.94.
The historical rank and industry rank for BioGaia AB's EV-to-EBITDA or its related term are showing as below:
OSTO:BIOG B'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.6 Med: 25.74 Max: 49.38
Current: 20.94
During the past 13 years, the highest EV-to-EBITDA of BioGaia AB was 49.38. The lowest was 12.60. And the median was 25.74.
OSTO:BIOG B's EV-to-EBITDA is ranked worse than 67.89% of 707
companies
in the Drug Manufacturers industry
Industry Median: 14.71
vs OSTO:BIOG B: 20.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-02), BioGaia AB's stock price is kr117.90.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr3.630. Therefore, BioGaia AB's PE Ratio for today is 32.48.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
BioGaia AB EV-to-EBITDA Historical Data
The historical data trend for BioGaia AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioGaia AB's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioGaia AB's EV-to-EBITDA falls into.
BioGaia AB EV-to-EBITDA Calculation
BioGaia AB's EV-to-EBITDA for today is calculated as:
BioGaia AB's current Enterprise Value is kr10,362 Mil.
BioGaia AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr495 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (OSTO:BIOG B) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BioGaia AB's share price for today is kr117.90.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of BioGaia AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:BIOG B has been successfully added to your 